We are pleased to announce that the collaborative rapid assessment, OTCA06, on “TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR THE TREATMENT OF PATIENTS AT INTERMEDIATE SURGICAL RISK” is available.
The health technology assessed is a bioprothesis in the aortic valve deployed using a catheter. The objective of this assessment was to evaluate the relative effectiveness and safety of this technology in contrast to traditional open-heart surgery.
Below is the documentation provided by the assessment authoring team:
OTCA06 TAVI FOR THE TREATMENT OFPATIENTS AT INTERMEDIATE SURGICAL RISK- FINAL
FINAL comments from external reviewers and manufacturers